Meeting
2023 ASCO Annual Meeting
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
Authors
Kathleen N. Moore
Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK
Kathleen N. Moore , Dhanusha Sabanathan , Yiqun Du , Huaxin Duan , Xiumin Li , Feng Wang , Omkar Marathe , Hua Yang , Vicky Makker , Whitfield Growdon , Jim Coward , Peng Zhao , Liming Liu , Rong Shi , Shengxue Liu , Wei Gu , Yang Qiu , Zhongyuan Zhu , Jian Zhang , Erika P. Hamilton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT05150691
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3023)
DOI
10.1200/JCO.2023.41.16_suppl.3023
Abstract #
3023
Poster Bd #
221
Abstract Disclosures
Similar Posters
First Author: R. Wendel Naumann
Poster
2020 Gastrointestinal Cancers Symposium
Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.
First Author: Jifang Gong
Poster
2023 ASCO Annual Meeting
A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.
First Author: Xiaojie Hu
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz